Document is current
Any future updates will be listed below
-
Authors
Harrington, Sean
Pyche, Jacob
Burns, Andrew R. http://orcid.org/0000-0002-8966-1280
Spalholz, Tina
Ryan, Kaetlyn T. http://orcid.org/0000-0002-2051-7969
Baker, Rachel J. http://orcid.org/0000-0001-5514-8887
Ching, Justin http://orcid.org/0000-0002-2511-216X
Rufener, Lucien
Lautens, Mark http://orcid.org/0000-0002-0179-2914
Kulke, Daniel
Vernudachi, Alexandre
Zamanian, Mostafa http://orcid.org/0000-0001-9233-1760
Deuther-Conrad, Winnie http://orcid.org/0000-0003-3168-3062
Brust, Peter http://orcid.org/0000-0001-5555-7058
Roy, Peter J. http://orcid.org/0000-0003-2959-2276
-
Funding
Funding for this research was provided by:
NSERC
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01 AI151171)
Gouvernement du Canada | Canadian Institutes of Health Research (313296, 173448)
- License Information
-
More Information
Article History
Received: 14 June 2022
Accepted: 17 March 2023
First Online: 31 March 2023
Competing interests
: Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by any author or affiliate organization. S.H., J.P., A.R.B., R.J.B., D.K., M.L. and P.J.R. have an issued U.S. patent covering the Nemacol scaffold (U.S. patent # 11,364,234) and additional patents pending related to the Nemacol scaffold. All molecules described herein can be used without restriction for academic purposes. The remaining authors declare no competing interests.
